

RECEIVED  
CENTRAL FAX CENTER

001/025

JUL 29 2005



Vertex Pharmaceuticals Incorporated  
130 Waverly Street • Cambridge, MA 02139-4242  
Tel. 617.444.6100 • Fax 617.444.6483  
<http://www.vpharm.com>

**FAX TRANSMISSION**

To	571-273-8300
Examiner	Deborah C. Lambkin
Group Art Unit	1626
From	Karen E. Brown
Date	July 29, 2005
Application No.	10/688,613
Attorney Docket No.	VPI/00-102 CON DIV3 US
Total Pages	22

**Message or Comment**

If any problems occur with this fax transmittal, please call (617) 444-6168 immediately.

RECEIVED  
OICE/IAP

AUG 01 2005

Rev. 3/8/05

RECEIVED  
CENTRAL FAX CENTER  
JUL 29 2005


VPI/00-102 CON DIV3 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/688,613  
Confirmation No.: 2448  
Filing Date: October 17, 2003  
Examiner: Deborah C. Lambkin  
Group Art Unit: 1626  
Applicants: Michael Hale et al.  
For: PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF  
ERK

Certificate of Facsimile Transmission Under 37 CFR 1.8

I hereby certify that this correspondence and any documents referred to as attached hereto is/are being facsimile transmitted to the United States Patent and Trademark Office on July 29, 2005.

  
Signature

Susan Batty-Gunn  
Typed or Printed Name

08/01/2005 HTECKLU1 00000011 500725 10688613

01 FC:1253 1020.00 DA

July 29, 2005  
Cambridge, Massachusetts

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Transmitted herewith: ☒ a Reply to Office Action; ☐ a Petition for Extension of Time; ☐ a substitute Specification; ☐ a Declaration; ☐ a Supplemental Declaration; ☐ a Power of Attorney; ☐ an Associate Power of Attorney; ☐ formal drawings; ☐ Notice of Appeal; ☐ Appeal Brief; ☒ Terminal Disclaimer; to be filed in the above-identified patent application.

**RECEIVED**  
CENTRAL FAX CENTER

**JUL 29 2005**

Applicants: Michael Hale et al.  
Application No.: 10/688,613

**FEE FOR ADDITIONAL CLAIMS**

☒ A fee for additional claims is not required.

☐ A fee for additional claims is required.

The additional fee has been calculated as shown below:

CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEES
TOTAL CLAIMS	24	-	24 * =	X \$ 50 = \$ 0
INDEPENDENT CLAIMS	1	-	3 ** =	X \$ 200 = \$ 0
FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM			+	\$ 360 = \$

\* If less than 20, insert 20.

\*\* If less than 3, insert 3.

TOTAL

\$ 0

☐ A check in the amount of \$\_\_\_ in payment of the filing fee is transmitted herewith.

☐ Please charge \$\_\_\_ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.

☒ The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

RECEIVED  
CENTRAL FAX CENTER

004/025

JUL 29 2005

Applicants: Michael Hale et al.  
Application No.: 10/688,613


EXTENSION FEE

- ☒ [X] The following extension is applicable to the Response filed herewith; ☐ [ ] \$120.00 extension fee for response within first month pursuant to 37 C.F.R. § 1.136(a); ☐ [ ] \$450.00 extension fee for response within second month pursuant to 37 C.F.R. § 1.136(a); ☒ [X] \$1,020.00 extension fee for response within third month pursuant to 37 C.F.R. § 1.136(a); ☐ [ ] \$1,590.00 extension fee for response within fourth month pursuant to 37 C.F.R. § 1.136(a); ☐ [ ] \$2,160.00 within fifth month pursuant to 37 C.F.R. § 1.136(a).
- ☐ [ ] A check in the amount of ☐ [ ] \$120.00; ☐ [ ] \$450.00; ☐ [ ] \$1,020.00; ☐ [ ] \$1,590.00; ☐ [ ] \$2,160.00 in payment of the extension fee is transmitted herewith.
- ☒ [X] Please charge the extension fee in the amount of ☐ [ ] \$120.00; ☐ [ ] \$450.00; ☒ [X] \$1,020.00; ☐ [ ] \$1,590.00; ☐ [ ] \$2,160.00 to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.
- ☒ [X] The Director is hereby authorized to charge payment of any additional fees required under 37 C.F.R. § 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

MISCELLANEOUS FEES

- ☐ [ ] Please charge \$\_\_\_\_\_ to Deposit Account No. 50-0725 for \_\_\_\_\_.

Respectfully submitted,

  
Karen E. Brown, Reg. No. 43,866  
Attorney/Agent for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6168  
Fax: (617) 444-6483

JUL 29 2005

Attorney Docket No. VPI/00-102 CON DIV3 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.: 10/688,613  
Confirmation No.: 2448  
Filing Date: October 17, 2003  
Examiner: Deborah C. Lambkin  
Group Art Unit: 1626  
Applicants: Michael Hale et al.  
For: PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF  
ERK

July 29, 2005  
Cambridge, Massachusetts

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT AND REPLY TO OFFICE ACTION**

Sir:

This is in response to the January 31, 2005 Office Action in the above-identified application. Applicants have concurrently herewith submitted a petition to extend the time for a reply by three month(s), up to and including July 31, 2005, and have authorized the Director to charge to Deposit Account No. 50-0725 the applicable fee under 37 C.F.R. § 1.17(a)(3). Consequently, this reply is timely submitted.

Amendments to the claims begin on page 2 of this Reply.

Remarks begin at page 12 of this Reply.

Rev. 3/8/05